Edition:
India

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

35.39USD
12:10am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$35.39
Open
$35.20
Day's High
$35.50
Day's Low
$34.85
Volume
13,309
Avg. Vol
8,224
52-wk High
$37.02
52-wk Low
$15.31

Latest Key Developments (Source: Significant Developments)

Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Albireo Pharma Inc ::ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS.ALBIREO PHARMA INC - ELOBIXIBAT APPROVED IN JAPAN FOR TREATMENT OF CHRONIC CONSTIPATION.ALBIREO PHARMA - JAPAN'S MINISTRY OF HEALTH, LABOR & WELFARE APPROVED NEW DRUG APPLICATION FOR ELOBIXIBAT FOR TREATMENT OF CHRONIC CONSTIPATION IN JAPAN.ALBIREO PHARMA INC - APPROVAL OF ELOBIXIBAT IN JAPAN TRIGGERS PAYMENTS TO ALBIREO SUBSIDIARY ELOBIX AB FROM EA PHARMA CO LTD.ALBIREO PHARMA - CO ‍EXPECTS TO INITIATE A PLANNED PHASE 3 STUDY OF A4250 BY SPRING OF 2018​.  Full Article

Albireo Announces Agreement With Healthcare Royalty Partners
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Albireo Pharma Inc ::ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN.ALBIREO PHARMA INC - ‍ALBIREO SUBSIDIARY ELIGIBLE TO RECEIVE UP TO $60 MILLION UNDER AGREEMENT​.ALBIREO PHARMA INC - ‍DECISION ON JAPANESE NEW DRUG APPLICATION FOR ELOBIXIBAT EXPECTED IN FIRST HALF OF 2018​.ALBIREO PHARMA -HCR OBTAINS RIGHT TO RECEIVE ROYALTIES, SALES MILESTONES FOR ELOBIXIBAT IN JAPAN THAT MAY BE PAYABLE BY EA PHARMA, UP TO A THRESHOLD​.ALBIREO PHARMA INC - ‍ELOBIX HAS RETAINED ITS RIGHT TO RECEIVE A MILESTONE PAYMENT FROM EA PHARMA IF ELOBIXIBAT IS APPROVED BY MHLW​.ALBIREO PHARMA INC - ‍ IF SPECIFIED THRESHOLD IS REACHED, ELOBIX WILL AGAIN BECOME ELIGIBLE TO RECEIVE ROYALTIES AND SALES MILESTONES FOR ELOBIXIBAT.  Full Article

Albireo posts Q3 loss per share $0.73‍​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Albireo Pharma Inc :Albireo reports third quarter 2017 financial results.Albireo Pharma Inc - ‍decision on potential approval of elobixibat in Japan expected in first half of 2018​.Albireo Pharma Inc - ‍revenue totaled $0 for Q3 of 2017 compared with $28,000 for Q3 of 2016​.Albireo Pharma Inc - qtrly loss per share $0.73‍​.Albireo Pharma - ‍expects current cash resources will meet operating requirements till end of 2019, assuming receipt of payment from EA Pharma in 2018​.  Full Article

Albireo Pharma files for mixed shelf of up to $125 million‍​
Saturday, 14 Oct 2017 

Oct 13 (Reuters) - Albireo Pharma Inc :Albireo Pharma Inc files for mixed shelf of up to $125 million - SEC filing‍​ ‍​.  Full Article

Biodel Q3 net loss $3.1 million
Friday, 12 Aug 2016 

Biodel Inc : Biodel reported a net loss of $3.1 million, or $0.05 per share, for quarter ended June 30, 2016 .Biodel reports third quarter fiscal year 2016 financial results.  Full Article

Biodel files proxy statement related to proposed merger with Albireo
Wednesday, 13 Jul 2016 

Biodel Inc : Files proxy statement related to proposed merger between Biodel and Albireo Limited Source: (http://bit.ly/29RsDuP ) Further company coverage: [BIOD.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Biodel Inc reports Q2 loss per share $0.09
Tuesday, 10 May 2016 

Biodel Inc : Biodel reports second quarter fiscal year 2016 financial results .Q2 loss per share $0.09.  Full Article